Neural stem cell transplantation and melatonin treatment in a 6‐hydroxydopamine model of Parkinson’s disease
Identifieur interne : 002553 ( Main/Exploration ); précédent : 002552; suivant : 002554Neural stem cell transplantation and melatonin treatment in a 6‐hydroxydopamine model of Parkinson’s disease
Auteurs : Rohita Sharma [Canada] ; Catherine R. Mcmillan [Canada] ; Lennard P. Niles [Canada]Source :
- Journal of Pineal Research [ 0742-3098 ] ; 2007-10.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cellule souche.
English descriptors
- KwdEn :
- Animals, Behavior, Animal (drug effects), C17.2 neural stem cells, Cell Line, Corpus striatum, Disease Models, Animal, Locus niger, Male, Melatonin, Melatonin (therapeutic use), Models, Neurons, Neuroprotection, Oxidopamine, Oxidopamine (metabolism), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (pathology), Parkinson Disease (surgery), Parkinson disease, Rats, Rats, Sprague-Dawley, Stem Cell Transplantation, Stem cell, Transplantation, Treatment, Tyrosine 3-Monooxygenase (metabolism), Tyrosine 3-monooxygenase, melatonin, neuroprotection, striatum, substantia nigra, tyrosine hydroxylase.
- MESH :
- chemical , metabolism : Oxidopamine, Tyrosine 3-Monooxygenase.
- chemical , therapeutic use : Melatonin.
- drug effects : Behavior, Animal.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- pathology : Parkinson Disease.
- surgery : Parkinson Disease.
- Animals, Cell Line, Disease Models, Animal, Male, Neurons, Rats, Rats, Sprague-Dawley, Stem Cell Transplantation.
Abstract
Abstract: Melatonin has multiple roles including neuroprotection. Melatonin signaling involves diverse targets including two G‐protein‐coupled receptors, MT1 and MT2, which have both been localized to the nigrostriatal pathway. Previous studies in our laboratory demonstrated preservation of tyrosine hydroxylase immunoreactivity, following chronic treatment with a physiological dose of melatonin, in the 6‐hydroxydopamine rat model of Parkinson’s disease. Additionally, we reported the presence of the melatonin MT1 receptor subtype in cultured C17.2 neural stem cells (NSCs). In the present study, we examined the effects of C17.2 NSC transplantation on dopaminergic denervation following 6‐hydroxydopamine lesioning in the rat striatum. Moreover, based on our detection of the MT1 in these cells, we examined the effects of combined C17.2 NSC transplantation and melatonin treatment, following striatal lesioning. Behavioral studies indicated a marked inhibition of apomorphine‐induced rotations in lesioned animals that received C17.2 NSC transplantation, melatonin, or the combined regimen. In addition, these treatments resulted in a significant protection of tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra of lesioned animals, when compared with untreated controls. Lesioned animals treated with C17.2 NSCs, melatonin or a combination of both agents exhibited no significant differences in the number of tyrosine hydroxylase‐positive cells in the substantia nigra or ventral tegmental area ipsilateral or contralateral to the lesioned striatum. These findings suggest that stem cell therapy and concomitant use of neuroprotective agents such as melatonin could be a viable approach in Parkinson’s disease.
Url:
DOI: 10.1111/j.1600-079X.2007.00469.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B13
- to stream Istex, to step Curation: 000B13
- to stream Istex, to step Checkpoint: 000A33
- to stream PubMed, to step Corpus: 001044
- to stream PubMed, to step Curation: 001044
- to stream PubMed, to step Checkpoint: 001044
- to stream Ncbi, to step Merge: 000810
- to stream Ncbi, to step Curation: 000810
- to stream Ncbi, to step Checkpoint: 000810
- to stream Main, to step Merge: 002796
- to stream PascalFrancis, to step Corpus: 000708
- to stream PascalFrancis, to step Curation: 000612
- to stream PascalFrancis, to step Checkpoint: 000623
- to stream Main, to step Merge: 002913
- to stream Main, to step Curation: 002553
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neural stem cell transplantation and melatonin treatment in a 6‐hydroxydopamine model of Parkinson’s disease</title><author><name sortKey="Sharma, Rohita" sort="Sharma, Rohita" uniqKey="Sharma R" first="Rohita" last="Sharma">Rohita Sharma</name></author><author><name sortKey="Mcmillan, Catherine R" sort="Mcmillan, Catherine R" uniqKey="Mcmillan C" first="Catherine R." last="Mcmillan">Catherine R. Mcmillan</name></author><author><name sortKey="Niles, Lennard P" sort="Niles, Lennard P" uniqKey="Niles L" first="Lennard P." last="Niles">Lennard P. Niles</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:744A9ECB9051F36426C15CA7F80BAE4964100E13</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1600-079X.2007.00469.x</idno><idno type="url">https://api-v5.istex.fr/document/744A9ECB9051F36426C15CA7F80BAE4964100E13/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B13</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B13</idno><idno type="wicri:Area/Istex/Curation">000B13</idno><idno type="wicri:Area/Istex/Checkpoint">000A33</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A33</idno><idno type="wicri:doubleKey">0742-3098:2007:Sharma R:neural:stem:cell</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17803521</idno><idno type="wicri:Area/PubMed/Corpus">001044</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001044</idno><idno type="wicri:Area/PubMed/Curation">001044</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001044</idno><idno type="wicri:Area/PubMed/Checkpoint">001044</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001044</idno><idno type="wicri:Area/Ncbi/Merge">000810</idno><idno type="wicri:Area/Ncbi/Curation">000810</idno><idno type="wicri:Area/Ncbi/Checkpoint">000810</idno><idno type="wicri:doubleKey">0742-3098:2007:Sharma R:neural:stem:cell</idno><idno type="wicri:Area/Main/Merge">002796</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0449187</idno><idno type="wicri:Area/PascalFrancis/Corpus">000708</idno><idno type="wicri:Area/PascalFrancis/Curation">000612</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000623</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000623</idno><idno type="wicri:doubleKey">0742-3098:2007:Sharma R:neural:stem:cell</idno><idno type="wicri:Area/Main/Merge">002913</idno><idno type="wicri:Area/Main/Curation">002553</idno><idno type="wicri:Area/Main/Exploration">002553</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neural stem cell transplantation and melatonin treatment in a 6‐hydroxydopamine model of Parkinson’s disease</title><author><name sortKey="Sharma, Rohita" sort="Sharma, Rohita" uniqKey="Sharma R" first="Rohita" last="Sharma">Rohita Sharma</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Mcmillan, Catherine R" sort="Mcmillan, Catherine R" uniqKey="Mcmillan C" first="Catherine R." last="Mcmillan">Catherine R. Mcmillan</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Niles, Lennard P" sort="Niles, Lennard P" uniqKey="Niles L" first="Lennard P." last="Niles">Lennard P. Niles</name><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Pineal Research</title><idno type="ISSN">0742-3098</idno><idno type="eISSN">1600-079X</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-10">2007-10</date><biblScope unit="volume">43</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="245">245</biblScope><biblScope unit="page" to="254">254</biblScope></imprint><idno type="ISSN">0742-3098</idno></series><idno type="istex">744A9ECB9051F36426C15CA7F80BAE4964100E13</idno><idno type="DOI">10.1111/j.1600-079X.2007.00469.x</idno><idno type="ArticleID">JPI469</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0742-3098</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Behavior, Animal (drug effects)</term><term>C17.2 neural stem cells</term><term>Cell Line</term><term>Corpus striatum</term><term>Disease Models, Animal</term><term>Locus niger</term><term>Male</term><term>Melatonin</term><term>Melatonin (therapeutic use)</term><term>Models</term><term>Neurons</term><term>Neuroprotection</term><term>Oxidopamine</term><term>Oxidopamine (metabolism)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (surgery)</term><term>Parkinson disease</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Stem Cell Transplantation</term><term>Stem cell</term><term>Transplantation</term><term>Treatment</term><term>Tyrosine 3-Monooxygenase (metabolism)</term><term>Tyrosine 3-monooxygenase</term><term>melatonin</term><term>neuroprotection</term><term>striatum</term><term>substantia nigra</term><term>tyrosine hydroxylase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Oxidopamine</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Melatonin</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Disease Models, Animal</term><term>Male</term><term>Neurons</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Stem Cell Transplantation</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cellule souche</term><term>Corps strié</term><term>Locus niger</term><term>Modèle</term><term>Mélatonine</term><term>Neuroprotection</term><term>Oxidopamine</term><term>Parkinson maladie</term><term>Traitement</term><term>Transplantation</term><term>Tyrosine 3-monooxygenase</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cellule souche</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Abstract: Melatonin has multiple roles including neuroprotection. Melatonin signaling involves diverse targets including two G‐protein‐coupled receptors, MT1 and MT2, which have both been localized to the nigrostriatal pathway. Previous studies in our laboratory demonstrated preservation of tyrosine hydroxylase immunoreactivity, following chronic treatment with a physiological dose of melatonin, in the 6‐hydroxydopamine rat model of Parkinson’s disease. Additionally, we reported the presence of the melatonin MT1 receptor subtype in cultured C17.2 neural stem cells (NSCs). In the present study, we examined the effects of C17.2 NSC transplantation on dopaminergic denervation following 6‐hydroxydopamine lesioning in the rat striatum. Moreover, based on our detection of the MT1 in these cells, we examined the effects of combined C17.2 NSC transplantation and melatonin treatment, following striatal lesioning. Behavioral studies indicated a marked inhibition of apomorphine‐induced rotations in lesioned animals that received C17.2 NSC transplantation, melatonin, or the combined regimen. In addition, these treatments resulted in a significant protection of tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra of lesioned animals, when compared with untreated controls. Lesioned animals treated with C17.2 NSCs, melatonin or a combination of both agents exhibited no significant differences in the number of tyrosine hydroxylase‐positive cells in the substantia nigra or ventral tegmental area ipsilateral or contralateral to the lesioned striatum. These findings suggest that stem cell therapy and concomitant use of neuroprotective agents such as melatonin could be a viable approach in Parkinson’s disease.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Hamilton (Ontario)</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Sharma, Rohita" sort="Sharma, Rohita" uniqKey="Sharma R" first="Rohita" last="Sharma">Rohita Sharma</name></region><name sortKey="Mcmillan, Catherine R" sort="Mcmillan, Catherine R" uniqKey="Mcmillan C" first="Catherine R." last="Mcmillan">Catherine R. Mcmillan</name><name sortKey="Niles, Lennard P" sort="Niles, Lennard P" uniqKey="Niles L" first="Lennard P." last="Niles">Lennard P. Niles</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002553 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002553 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:744A9ECB9051F36426C15CA7F80BAE4964100E13
|texte= Neural stem cell transplantation and melatonin treatment in a 6‐hydroxydopamine model of Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.29. |  |